Alveolar-capillary barrier dysfunction is a defining feature of acute lung injury. Evolving therapies developed in animal models of lung injury have resulted in the generation of an array of techniques, drugs, and novel small molecules that might protect patients who have acute lung injury by enhancing the function of the alveolar epithelial barrier. Some of these novel strategies are being tested in clinical trials. Investigators are optimistic that the completion of these trials will provide new, molecular-based therapies that will improve outcomes in patients who have lung injury.
ASJC Scopus subject areas
- Pulmonary and Respiratory Medicine